We conducted a prospective descriptive study on blood plasmas from pregnant women over a period of three months, from January 1 to March 31, 2022. A total of 98 blood plasma samples from pregnant women were analyzed. Sampling was carried out systematically on all blood samples from pregnant women who had attended the laboratory of the Blanche Gomez Mother-Child Specialty Hospital in Brazzaville, Congo, for biological investigations. IgG and IgM assay were performed using the Architect i1000SRanalyzer (ABBOTT), using the microparticle chemiluminescence immunological technique.
Background: Rubella constitutes an important public health problem due to the potential teratogenic effect of the virus when infection occurs early in pregnancy. The objective of this study was to determine the rubella serological profile of pregnant women. Methodology: We conducted a prospective cross-sectional study from January 1 to March 31, 2022, a period of 3 months. Venous blood samples from 98 pregnant women who came for biological investigations to the laboratory of the Blanche Gomez Specialized Mother-Child Hospital (Brazzaville, Congo) were analyzed. The determination of immunoglobulins G and M was carried out on the Architect i1000SR analyzer (ABBOTT) using the chemiluminescence immunological technique